KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vir Biotechnology (VIR) Other Operating Expenses (2018 - 2025)

Vir Biotechnology's Other Operating Expenses history spans 7 years, with the latest figure at $26000.0 for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 100.8% to $26000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$156000.0, a 100.44% decrease, with the full-year FY2025 number at -$156000.0, down 100.44% from a year prior.
  • Other Operating Expenses hit $26000.0 in Q4 2025 for Vir Biotechnology, up from -$11000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for VIR hit a ceiling of $90.1 million in Q1 2022 and a floor of -$3.3 million in Q4 2024.
  • Historically, Other Operating Expenses has averaged $13.9 million across 5 years, with a median of $5.4 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: surged 2340.65% in 2022 and later crashed 190.91% in 2025.
  • Tracing VIR's Other Operating Expenses over 5 years: stood at $56.9 million in 2021, then crashed by 89.46% to $6.0 million in 2022, then dropped by 6.29% to $5.6 million in 2023, then plummeted by 158.02% to -$3.3 million in 2024, then skyrocketed by 100.8% to $26000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for VIR at $26000.0 in Q4 2025, -$11000.0 in Q3 2025, and -$161000.0 in Q2 2025.